Optimal Control Model For Male Circumcision In Hiv/Aids Preventions
The Transactions of the Nigerian Association of Mathematical Physics · 28.02.2025
DOI: 10.60787/tnamp.v21.473 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Transactions of the Nigerian Association of Mathematical Physics, erschienen am 28.02.2025. Verfasst von Thomas und 3 weiteren Autor:innen.
Abstract (Originalsprache)
This work presents the mathematical model of the transmission dynamics of HIV/AIDS infection with the circumcision of the susceptible and infected population. It describes the interaction between the susceptible, the infected and removed population which results in a system of ordinary differential equation . The control u1(t) u2(t), u3(t) representing the efficiency of circumcised/prevention devices, efficiency of the vaccine therapy in preventing HIV infection, the efficiency of drug in inhibiting the virus strain and effort on infected human that are circumcised and those that are not circumcised to increase the number of removed individuals respectively, were introduced, resulting in a system of differential equation with optimal control The control efforts for the reduction of transmission dynamics of the infection were established using Pontryagin’s Maximum Principle and optimality condition.
Schlagwörter
Zitieren
APA
Thomas, S., H., Udofia, & S., E. (2025). Optimal Control Model For Male Circumcision In Hiv/Aids Preventions. The Transactions of the Nigerian Association of Mathematical Physics. https://doi.org/10.60787/tnamp.v21.473
Vancouver
Thomas, S. H, Udofia, S. E. Optimal Control Model For Male Circumcision In Hiv/Aids Preventions. The Transactions of the Nigerian Association of Mathematical Physics. 2025. doi:10.60787/tnamp.v21.473
BibTeX
@article{Thomas2025,
author = {Thomas and S., H. and Udofia and S., E.},
title = {Optimal Control Model For Male Circumcision In Hiv/Aids Preventions},
journal = {The Transactions of the Nigerian Association of Mathematical Physics},
year = {2025},
doi = {10.60787/tnamp.v21.473}
}
EUVIMED